Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Leases (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Operating Leases readings, the most recent being $11.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 17.12% year-over-year to $11.9 million, compared with a TTM value of $11.9 million through Dec 2025, up 17.12%, and an annual FY2025 reading of $11.9 million, up 17.12% over the prior year.
  • Operating Leases hit $11.9 million in Q4 2025 for Apellis Pharmaceuticals, down from $13.7 million in the prior quarter.
  • The five-year high for Operating Leases was $19.9 million in Q1 2021, with the low at $8.3 million in Q2 2025.
  • Median Operating Leases over the past 5 years was $12.6 million (2023), compared with a mean of $13.5 million.
  • The sharpest move saw Operating Leases soared 78.16% in 2021, then fell 28.83% in 2023.
  • Year by year, Operating Leases stood at $17.1 million in 2021, then dropped by 15.98% to $14.4 million in 2022, then decreased by 20.19% to $11.5 million in 2023, then dropped by 10.94% to $10.2 million in 2024, then increased by 17.12% to $11.9 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $11.9 million, $13.7 million, and $8.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.